SureTrader
Home > Boards > US OTC > Biotechs >

Kasten Inc. (KAST)

KAST RSS Feed
Add KAST Price Alert      Hide Sticky   Hide Intro
Moderator: BERKSHIRE AGENT , whatarush12, PhenixBleu
Search This Board: 
Last Post: 4/12/2018 9:54:07 AM - Followers: 59 - Board type: Free - Posts Today: 0

Kasten, Inc. dba Dakota Life Sciences (KAST)
OTC Pink - Current Information - PCAOB Audit & 2018 Uplist Plan Underway

522 N. Main Avenue, #202, Sioux Falls, SD 57104
888-679-3679
skeough@dakotalifesci.com

Additional Offices are located in California and Connecticut 


AUTHORIZED 950,000,000                           OUTSTANDING  62,501,211                           FLOAT  20,501,211

Kasten, Inc. (dba DAKOTA Life Sciences) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals
designed to prevent and treat serious conditions arising both in hospital and community settings. We are principally focused on delivering solutions to those people
who are affected by antimicrobial resistance and who need superior pharmaceutical products at affordable prices.


FILINGS                                        NEWS                                       PROFILE                                   WEBSITE



-- INTELLECTUAL PROPERTY --

US PATENT 7198794 B1 - Assigned to Thru Pharma dba Dakota Life Sciences by Inventor Lorri Riley, a well-respected Podiatrist. Dr. Riley has an active medical and research podiatry practice,
and has worked closely with Dakota Life Sciences since their acquisition of her intellectual property in 2013.

US PATENT 9693968 B2 - Exclusive global distribution and development rights to Lotilibcin, a first-line Anti-MRSA and acne product candidate.  Lotilibcin, is recognized by the World Health
Organization and is listed in the United States National Library of Medicine and in the Chemical Abstract Service (CAS) with Registry Number 169148-84-9. This Patent was Granted July 2017.


Site Specific Penetration Technology (SSPT) is a proprietary drug delivery technology that enables direct application of medications at the site where the drug is needed, rather than relying on
systemic delivery through the blood stream.  The SSPT brand of drug delivery system restores resistance-prone pharmaceuticals, like early generation tetracycline, into newly active,
high efficacy drugs once again capable of reliably killing both resistant and non-resistant bacteria.

The SSPT technology is at the core of litigation efforts between Kasten/OPD Holdings (Plaintiff) and Defendants ViaDerma (VDRM), its CEO Christopher Ayo Otiko, and the technology inventor
Howard Phillips. A Complaint was filed in South Dakota in 2017. The case was Dismissed solely on jurisdictional grounds for the Federal Trademark elements which belong in California or Oklahoma. 
The Breach of Contract claims can be refiled against named individuals in South Dakota.  The case is available for review on PACER.  Docket Item 57 is the Complaint and Exhibits with Otiko's
Independent Contractor Agreement. They are eye opening in light of Otiko's decision to start ViaDerma using SSPT.  See the NEWS RELEASE issued February 26, 2018 for further information. 

 


 
DAILY WEEKLY
 


 
SureTrader
KAST
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#4300  Sticky Note Letter to Kasten Inc. Shareholders from President Steven PhenixBleu 03/13/18 11:37:22 AM
#4390   Over the past few months, I’ve been following Southmead 04/10/18 12:03:08 PM
#4389   I find it funny that they didn’t file Southmead 04/10/18 09:29:17 AM
#4388   ?? 04/09/2018 Annual Report - Kasten Financials and uglypug 04/10/18 07:52:21 AM
#4387   No annual filing? Southmead 04/06/18 10:30:26 AM
#4385   The links in the iBox also lead to PhenixBleu 03/17/18 05:51:24 AM
#4384   Spot on! Great assessment. Couldn’t agree more! whatarush12 03/16/18 05:46:25 PM
#4382   Yep, lol, gonna have to take that huge kennyt 335 03/16/18 04:36:53 PM
#4381   Sometime after Keough merges with another unsuspecting (Sucker) SchlumpyStock-Picker 03/16/18 04:27:08 PM
#4380   My sell is at .06 and .07..... how kennyt 335 03/16/18 03:07:09 PM
#4377   Kasten lawsuit was dismissed without prejudice! Southmead 03/16/18 12:24:07 PM
#4376   "Flat line" SchlumpyStock-Picker 03/16/18 12:20:30 PM
#4375   LOLOLOL Chicagojosh 03/16/18 12:03:43 PM
#4374   If you look at the bright side, nobody SchlumpyStock-Picker 03/16/18 12:01:21 PM
#4371   the links in the IBox show the exact Chicagojosh 03/16/18 11:32:57 AM
#4370   As clearly annotated in each of the 2017 PhenixBleu 03/16/18 11:26:40 AM
#4369   Dakota has no financials on their website to Chicagojosh 03/16/18 11:18:55 AM
#4368   The Stickied Letter to Shareholders provides a much PhenixBleu 03/16/18 11:12:29 AM
#4367   Kasten, ZERO revenues dating back to 2013, ZERO Chicagojosh 03/16/18 11:08:09 AM
#4366   looks like another high volume day over here lol Chicagojosh 03/16/18 10:06:19 AM
#4365   Short selling and other forms of market manipulation PhenixBleu 03/16/18 09:47:04 AM
#4364   My opinions are based on the Independent Contract PhenixBleu 03/16/18 09:43:32 AM
#4363   How does a stock lose 5% with ZERO Volume?! MegaVerde 03/16/18 09:34:03 AM
#4362   In your OPINION. I think most disagree with you. MegaVerde 03/16/18 09:26:15 AM
#4361   Development stage businesses always make great flips. Has PhenixBleu 03/15/18 04:26:29 PM
#4360   Looks like some folks are bailing the sinking retired early 03/15/18 03:50:57 PM
#4359   I agree there is no "business partner agreement" PhenixBleu 03/15/18 11:26:26 AM
#4358   I actually have a pacer monitor account so hghscurry 03/15/18 10:56:28 AM
#4357   Otiko's contract with Keough is Attachment 4 in PhenixBleu 03/15/18 09:51:55 AM
#4356   There sure is a lot of RED in SchlumpyStock-Picker 03/14/18 10:44:12 PM
#4355   How could a lawer invent medicine what freestock 03/14/18 06:10:40 PM
#4354   There was no contract with Keough. Keough was hghscurry 03/14/18 04:38:27 PM
#4353   Claims are backed by documentary evidence in the PhenixBleu 03/14/18 04:25:40 PM
#4352   And all of these claims were written by MegaVerde 03/14/18 04:16:21 PM
#4351   I don't write false information. It all comes PhenixBleu 03/14/18 04:10:28 PM
#4350   Completely false. Keough put his name on the hghscurry 03/14/18 03:43:23 PM
#4343   100% accurate! Heading back down to .02 whatarush12 03/14/18 11:25:28 AM
#4342   Howard Phillips sold exclusive rights to the technology PhenixBleu 03/14/18 11:21:01 AM
#4341   Do you mean Keough had bought a horse thiefscamfraud 03/14/18 11:20:41 AM
#4340   Keough was hired as a patent attorney not hghscurry 03/14/18 11:15:50 AM
#4339   The Judge DENIED Motion 58 - Award of PhenixBleu 03/14/18 11:15:45 AM
#4338   Again - How could you have a guy Here Today 03/14/18 11:07:41 AM
#4337   That's a misconception that arises from Otiko's failure PhenixBleu 03/14/18 11:01:15 AM
#4336   PhenixBleu is right. KAST is good. Give me thiefscamfraud 03/14/18 10:57:36 AM
#4335   Why would anyone want to invest their hard Here Today 03/14/18 10:56:37 AM
#4331  Restored Count 6: Breach of Independent Contractor Agreement (Otiko) PhenixBleu 03/14/18 10:51:36 AM
#4330  Restored Wrong again. Viaderma Owns this technology and Keough MegaVerde 03/14/18 10:51:36 AM
#4326  Restored Weird...that describes ViaDerma PERFECTLY! Considering Kasten has plans PhenixBleu 03/14/18 09:17:43 AM
#4325   Lol JJZander 03/14/18 09:09:24 AM
#4324   Good morning KAST! BERKSHIRE AGENT 03/14/18 07:01:00 AM
#4323   Ugggggly chart! Wow! Trips coming, then grey market whatarush12 03/14/18 03:33:34 AM
PostSubject